Back to Authors

Villaflor, Victoria

https://orcid.org/0000-0002-9111-1034

A5055165247 | I40347166

Mayo Clinic

University of Chicago

Citations 2

A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6060-6060

10.1200/jco.2015.33.15_suppl.6060

Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck cancers: Results of the randomized PII MAESTRO study.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6089-6089

10.1200/jco.2014.32.15_suppl.6089